SCHEMBL24834901

SCHEMBL24834901

COC(=O)c1ccc(C2=CCCCC2)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 3/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ATM Q13315 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
XDH P47989 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6068829 0.85 CA12 (0.41) ALDH1A1MAPTSMN1; SMN2NPSR1CYP1A2
SCHEMBL3904050 0.83 NOTUM (0.49) PDE3BPDE3AALDH1A1MAPTSMN1; SMN2
SCHEMBL24834757 0.82 POLB (0.41) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL2310183 0.81 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2NPSR1ATMCA1
SCHEMBL2310188 0.81 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2NPSR1ATMCA1
SCHEMBL2530396 0.81 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2NPSR1ATMCA1
SCHEMBL2501250 0.81 CA12 (0.50) ALDH1A1MAPTSMN1; SMN2NPSR1CYP1A2
SCHEMBL4950570 0.81 CA12 (0.41) ALDH1A1MAPTSMN1; SMN2NPSR1CYP1A2
SCHEMBL6651987 0.81 KDM4E (0.42) ALDH1A1MAPTSMN1; SMN2NPSR1ATM
SCHEMBL27359297 0.80 PTPRC (0.41) GRM2ALDH1A1SMN1; SMN2NPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002396-A1 THERAPEUTIC COMPOUNDS GENENTECH, INC. (US) 2023-01-05 US disclosed
EP-4065230-A1 THERAPEUTIC COMPOUNDS Genentech, Inc. (US) 2022-10-05 EP disclosed
CN-114786778-A Therapeutic compounds 基因泰克公司 2022-07-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002396-A1 THERAPEUTIC COMPOUNDS YAP1, YES1, TEAD2 GRM2 4013/4885PDE3B 3078/4885PDE3A 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.